Author Correction: The beneficial effects of Lactobacillus reuteri ADR-1 or ADR-3 consumption on type 2 diabetes mellitus: a randomized, double-blinded, placebo-controlled trial

Correction to: Scientific Reports 10.1038/s41598-018-35014-1, published online 14 November 2018

This Article contains errors in the Materials and Methods and the Results section.

In the Materials and Methods section under subheading ‘The recruitment of participants’,

“The exclusion criteria were as follows: pregnancy; the presence of other diseases, including cancers (with the exception of well-controlled benign tumors), kidney failure/dialysis, heart diseases, stroke, or autoimmune diseases; the use of medications, including anti-diabetes drugs, and antibiotics, or other probiotic products <4 weeks before randomization; an AST/ALT level >3-fold the normal range; participation in other clinical trials; and the presence of other medical conditions that might jeopardize compliance with the protocol (e.g., malabsorption syndrome or an inability to take orally administered drugs).”

should read:

“The exclusion criteria were as follows: pregnancy; the presence of other diseases, including cancers (with the exception of well-controlled benign tumors), kidney failure/dialysis, heart diseases, stroke, or autoimmune diseases; the use of medications, including anti-diabetes herbs, and antibiotics, or dietary supplements for diabetes care as well as other probiotic products <4 weeks before randomization; an AST/ALT level >3-fold the normal range; participation in other clinical trials; and the presence of other medical conditions that might jeopardize compliance with the protocol (e.g., malabsorption syndrome or an inability to take orally administered drugs).”

In the Results section under subheading ‘L. reuteri strain ADR-1 displayed beneficial effects in a T2DM rat model’.

“Reductions in serum antioxidant proteins such as glutathione reductase (GPX) and superoxide dismutase (SOD) were also observed in HFD rats with oral administration of ADR-1 (Fig. 1D).”

should read:

Recovery of down-regulated expression in glutathione reductase (GPX) and superoxide dismutase (SOD) was observed in HFD rats with oral administration of ADR-1 (Fig. 1D).